Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Cites Long-Term Precedent In Blocking Retail Genetic Screening Plans

This article was originally published in The Tan Sheet

Executive Summary

A particularly public pre-emptive stance by FDA's in vitro diagnostics oversight office halts Pathway Genomics' plans to start selling genetic screening test sample collection kits out of Walgreens stores, but the office's director stresses the move does not signal any changes to its enforcement policy for laboratory-developed tests

You may also be interested in...



Pharmacy Interests Back BTC Models For Third Class

Retailers CVS and Walmart, as well as the National Association of Chain Drug Stores, advocate for a central role for pharmacists in enabling a new class of nonprescription drugs. In comments to FDA, NACDS also supports a switch model that will protect the existing OTC class.

Pharmacy Interests Back BTC Models For Third Class

Retailers CVS and Walmart, as well as the National Association of Chain Drug Stores, advocate for a central role for pharmacists in enabling a new class of nonprescription drugs. In comments to FDA, NACDS also supports a switch model that will protect the existing OTC class.

Pharmacy Interests Back BTC Models For Third Class

Retailers CVS and Walmart, as well as the National Association of Chain Drug Stores, advocate for a central role for pharmacists in enabling a new class of nonprescription drugs. In comments to FDA, NACDS also supports a switch model that will protect the existing OTC class.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS104109

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel